Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Zoeken op expertise, naam of affiliatie
A clinical development paradigm for cancer vaccines and related biologics
Axel Hoos
, Giorgio Parmiani
, Kristen Hege
, Mario Sznol
, Hans Loibner
,
Alexander Eggermont
, Walter Urba
, Brent Blumenstein
, Natalie Sacks
, Ulrich Keilholz
, Geoffrey Nichol
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel recenseren
›
peer review
257
Citaten (Scopus)
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'A clinical development paradigm for cancer vaccines and related biologics'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Clinical Development
100%
Cancer-related
100%
Cancer Vaccine
100%
Efficacy Trial
100%
Development Paradigm
100%
Biologic Activity
66%
Immune Response
50%
Phase II Trial
50%
Cytotoxic Agents
50%
Therapeutic Vaccine
50%
Combination Therapy
33%
Randomized Phase II Trial
33%
Well-defined
33%
Developmental Processes
16%
Clinical Trials
16%
Clinical Benefit
16%
Pharmaceutical Industry
16%
Follow-up Time
16%
Clinical Characteristics
16%
U.S. Food
16%
Further Development
16%
Informed Decision-making
16%
Molecular Markers
16%
Clinical Activity
16%
Phase II Study
16%
Heterogeneous Groups
16%
Clinical Endpoints
16%
Historical Controls
16%
Progressive Disease
16%
Early Response
16%
Biologic Markers
16%
Rapidly Progressive
16%
Statistical Methods
16%
Immune Markers
16%
Host Immune Response
16%
Neoadjuvant Setting
16%
Unique Characteristics
16%
Tumor Response Rate
16%
Trial Design
16%
Vaccine Trial
16%
Consensus Process
16%
Vaccine Effectiveness
16%
Metastatic Setting
16%
Biologic Features
16%
Molecular Response
16%
Developmental Issues
16%
Oncology Drug Development
16%
Early Decision
16%
General Type
16%
Endpoint Control
16%
Adaptive Design
16%
2-phase
16%
Clinical Development Plan
16%
Safety Database
16%
Biotechnology Industry
16%
Design Elements
16%
Trigger Points
16%
Medicine and Dentistry
Biological Product
100%
Tumor Vaccine
100%
Immune Response
37%
Cytotoxic Agent
37%
Clinical Trial
25%
Combination Therapy
25%
Neoplasm
12%
Disease
12%
Oncology
12%
Decision Making
12%
Health Care Cost
12%
Clinical Study
12%
Statistical Analysis
12%
Arm
12%
Immune System
12%
Progressive Disease
12%
Molecular Marker
12%
Immunity
12%
Vaccine
12%
Trigger Point
12%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
100%
Tumor Vaccine
100%
Cytotoxic Agent
37%
Clinical Trial
25%
Disease
25%
Combination Therapy
25%
Neoplasm
12%
Clinical Study
12%
Molecular Marker
12%
Drug Development
12%
Vaccine
12%
Biochemistry, Genetics and Molecular Biology
Immune Response
100%
Clinical Trial
66%
Immunity
66%
Genetic Marker
33%
Clinical Study
33%
Decision Making
33%
Trigger Point
33%